MENU
+Compare
IDYA
Stock ticker: NASDAQ
AS OF
Jan 23, 10:41 AM (EDT)
Price
$22.98
Change
-$0.16 (-0.69%)
Capitalization
2B

IDYA IDEAYA Biosciences Forecast, Technical & Fundamental Analysis

an oncology-focused precision medicine company committed to the discovery and development of targeted cancer therapeutics for patient populations selected using molecular diagnostics.

Industry Biotechnology
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IDYA with price predictions
Jan 08, 2025

Momentum Indicator for IDYA turns negative, indicating new downward trend

IDYA saw its Momentum Indicator move below the 0 level on January 07, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 107 similar instances where the indicator turned negative. In of the 107 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IDYA entered a downward trend on January 08, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 58 cases where IDYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IDYA just turned positive on December 26, 2024. Looking at past instances where IDYA's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.694) is normal, around the industry mean (15.076). P/E Ratio (0.000) is within average values for comparable stocks, (88.202). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.833). IDYA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (454.545) is also within normal values, averaging (264.879).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IDYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

IDYA is expected to report earnings to rise 4.80% to -62 cents per share on April 01

IDEAYA Biosciences IDYA Stock Earnings Reports
Q4'24
Est.
$-0.63
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.14
Q1'24
Missed
by $0.02
Q4'23
Missed
by $0.05
The last earnings report on November 04 showed earnings per share of -60 cents, beating the estimate of -62 cents. With 3.27K shares outstanding, the current market capitalization sits at 2.00B.
A.I. Advisor
published General Information

General Information

an oncology-focused precision medicine company committed to the discovery and development of targeted cancer therapeutics for patient populations selected using molecular diagnostics.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7000 Shoreline Court
Phone
+1 650 443-6209
Employees
124
Web
https://www.ideayabio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPYGX20.950.06
+0.29%
Spyglass Growth Institutional
PAAOX15.480.03
+0.19%
T. Rowe Price Asia Opportunities Advisor
BROIX19.32N/A
N/A
BlackRock Advantage International Instl
ALOYX19.23N/A
N/A
Alger Mid Cap Focus Y
PAMCX97.78-0.11
-0.11%
T. Rowe Price Mid-Cap Growth Adv

IDYA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.04%
GRI - IDYA
54%
Loosely correlated
-3.31%
PLRX - IDYA
48%
Loosely correlated
-1.36%
PRME - IDYA
48%
Loosely correlated
+9.28%
ETNB - IDYA
47%
Loosely correlated
+2.58%
RCKT - IDYA
47%
Loosely correlated
+3.15%
More